From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Celltech Group
HeadquartersSlough, UK
Key people
Goran Ando (CEO)

Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index.


The Company was founded by Gerard Fairtlough in 1980 with finance from the National Enterprise Board.[1]

In 1999 the Company led consolidation in the UK biosciences market merging with Chiroscience plc and then buying Medeva plc.[2] Then in 2000 it bought Cistron, a US biosciences business.[3] It expanded into Germany in 2001 buying Thiemann, a German biosciences business,[4] and went on to buy Oxford Glycosciences in July 2003 for £102m.[5] Celltech was acquired by UCB, a Belgian drugmaker, in 2004.[6] Since then it has been known as UCB Celltech.


The Company was engaged in research and development of therapies for patients with serious diseases. Products included:[7]

See also[edit]


  1. ^ Pharmatelevision
  2. ^ UK Biotech Industry Consolidates As Celltech Buys Medeva for $915m[permanent dead link]
  3. ^ UK's Celltech Buys Cistron of the US[permanent dead link]
  4. ^ Celltech acquires German sales and marketing firm Thiemann for $44.6 mill
  5. ^ ISIS Archived September 17, 2014, at the Wayback Machine.
  6. ^ "Celltech sold to Belgian firm in £1.5bn deal". The Guardian. 18 May 2004.
  7. ^ Businessweek: Celltech Group Archived September 8, 2012, at the Wayback Machine.
  8. ^ Damle, NK; Frost, P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in Pharmacology. 3 (4): 386–90. doi:10.1016/S1471-4892(03)00083-3. PMID 12901947.